Frequency of Self-Reported COPD Exacerbation and Airflow Obstruction in Five Latin American Cities The Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) Study

被引:30
|
作者
Montes de Oca, Maria [1 ]
Talamo, Carlos [1 ]
Halbert, Ronald J. [2 ]
Perez-Padilla, Rogelio [3 ]
Victorina Lopez, Maria [4 ]
Muino, Adriana [4 ]
Jardim, Jose Roberto B. [5 ]
Valdivia, Gonzalo
Pertuze, Julio [6 ,7 ]
Moreno, Dolores [1 ]
Menezes, Ana Maria B. [8 ]
机构
[1] Cent Univ Venezuela, Fac Med, Hosp Univ Caracas, Serv Neumonol, Caracas, Venezuela
[2] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA
[3] Inst Resp Dis, Mexico City, DF, Mexico
[4] Univ Republica, Fac Med, Hosp Maciel, Montevideo, Uruguay
[5] Univ Fed Sao Paulo, Sao Paulo, Brazil
[6] Pontificia Univ Catolica Chile, Dept Salud Publ, Fac Med, Santiago, Chile
[7] Pontificia Univ Catolica Chile, Catedra Neumol, Fac Med, Santiago, Chile
[8] Univ Fed Pelotas, Fac Med, Pelotas, RS, Brazil
关键词
DISEASE EXACERBATION; HOSPITAL ADMISSION; RISK-FACTORS; INFLAMMATION; POPULATION; PREVENTION; PREVALENCE; DIAGNOSIS;
D O I
10.1378/chest.08-2081
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Recurrent exacerbations are common in COPD patients. Limited information exists regarding exacerbation frequency in COPD patients from epidemiologic studies. We examined the frequency of self-reported exacerbations and the factors influencing exacerbation frequency among COPD patients in a population-based study conducted in Latin America. Methods: We used a post-bronchodilator FEV1/FVC ratio of < 0.70 to define COPD. Exacerbation was self-reported and defined by symptoms (deterioration of breathing symptoms that affected usual daily activities or caused missed work). Results.: Spirometry was performed in 5,314 subjects. There were 759 subjects with airflow limitation; of these, 18.2% reported ever having had an exacerbation, 7.9% reported having an exacerbation, and 6.2% reported having an exacerbation requiting at least a doctor visit within the past year. The proportion of individuals with an exacerbation significantly increased by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, from 4.2% in stage I to 28.9% in stages 3 and 4. The self-reported exacerbation rate was 0.58 exacerbations per year. The rate of exacerbations requiring at least a doctor visit and length of stay in hospital due to exacerbations also increased as COPD severity progressed. The factors associated with having an exacerbation in the past year were dyspnea, prior asthma diagnosis, receiving any respiratory therapy, and disease severity of GOLD stages 3 and 4. Conclusions: The proportion of individuals with airflow limitation and self-reported exacerbation increases as the disease severity progresses. Dyspnea, prior asthma diagnosis, receiving any respiratory therapy, and more severe obstruction were significantly associated with having an exacerbation in the past year. (CHEST 2009; 136:71-78)
引用
收藏
页码:71 / 78
页数:8
相关论文
共 3 条
  • [1] Airflow Obstruction in Never Smokers in Five Latin American Cities: The PLATINO Study
    Perez-Padilla, Rogelio
    Fernandez, Rosario
    Lopez Varela, Maria Victorina
    Montes de Oca, Maria
    Muino, Adriana
    Talamo, Carlos
    Brito Jardim, Jose Roberto
    Valdivia, Gonzalo
    Baptista Menezes, Ana Maria
    ARCHIVES OF MEDICAL RESEARCH, 2012, 43 (02) : 159 - 165
  • [2] Health status perception and airflow obstruction in five Latin American cities: The PLATINO study
    Montes de Oca, Maria
    Talamo, Carlos
    Halbert, Ronald J.
    Perez-Padilla, Rogelio
    Victorina Lopez, Maria
    Muino, Adriana
    Jardim, Jose Roberto B.
    Valdivia, Gonzalo
    Pertuze, Julio
    Moreno, Dolores
    Menezes, Ana Maria B.
    RESPIRATORY MEDICINE, 2009, 103 (09) : 1376 - 1382
  • [3] Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: The PLATINO study
    Montes de Oca, Maria
    Perez-Padilla, Rogelio
    Talamo, Carlos
    Halbert, Ronald J.
    Moreno, Dolores
    Victorina Lopez, Maria
    Muino, Adriana
    Jose Roberto, B. Jardim
    Valdivia, Gonzalo
    Pertuze, Julio
    Ana Maria, B. Menezes
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (01) : 29 - 35